MX2020003395A - Composiciones y metodos para tratar linfoma difuso de celulas b grandes. - Google Patents

Composiciones y metodos para tratar linfoma difuso de celulas b grandes.

Info

Publication number
MX2020003395A
MX2020003395A MX2020003395A MX2020003395A MX2020003395A MX 2020003395 A MX2020003395 A MX 2020003395A MX 2020003395 A MX2020003395 A MX 2020003395A MX 2020003395 A MX2020003395 A MX 2020003395A MX 2020003395 A MX2020003395 A MX 2020003395A
Authority
MX
Mexico
Prior art keywords
compositions
methods
cell lymphoma
diffuse large
treating diffuse
Prior art date
Application number
MX2020003395A
Other languages
English (en)
Spanish (es)
Inventor
Zachary ZIMMERMAN
Xiaohong Alicia Zhang
Peter Christopher Holland
Janet Franklin
Gregory Friberg
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2020003395A publication Critical patent/MX2020003395A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2020003395A 2017-10-13 2018-10-12 Composiciones y metodos para tratar linfoma difuso de celulas b grandes. MX2020003395A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762571870P 2017-10-13 2017-10-13
PCT/US2018/055667 WO2019075366A1 (en) 2017-10-13 2018-10-12 COMPOSITIONS AND METHODS FOR TREATING DIFFUSED LYMPHOMA WITH LARGE B CELLS

Publications (1)

Publication Number Publication Date
MX2020003395A true MX2020003395A (es) 2020-08-03

Family

ID=64110107

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003395A MX2020003395A (es) 2017-10-13 2018-10-12 Composiciones y metodos para tratar linfoma difuso de celulas b grandes.
MX2024001888A MX2024001888A (es) 2017-10-13 2020-07-13 Composiciones y metodos para tratar linfoma difuso de celulas b grandes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024001888A MX2024001888A (es) 2017-10-13 2020-07-13 Composiciones y metodos para tratar linfoma difuso de celulas b grandes.

Country Status (15)

Country Link
US (1) US20200262919A1 (https=)
EP (1) EP3694520A1 (https=)
JP (2) JP2020536923A (https=)
KR (1) KR20200068655A (https=)
CN (1) CN111212646A (https=)
AU (1) AU2018347457A1 (https=)
BR (1) BR112020007203A2 (https=)
CA (1) CA3075291A1 (https=)
CL (1) CL2020000973A1 (https=)
EA (1) EA202090565A1 (https=)
IL (1) IL273805A (https=)
MX (2) MX2020003395A (https=)
SG (1) SG11202002374RA (https=)
TW (1) TW201922283A (https=)
WO (1) WO2019075366A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2021183861A1 (en) * 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
US20230331844A1 (en) * 2020-10-12 2023-10-19 Greffex, Inc. Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses
JP2026502330A (ja) * 2022-11-01 2026-01-22 テネオツー・インコーポレイテッド 非ホジキンリンパ腫を治療する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
US10751412B2 (en) 2015-05-29 2020-08-25 Merck Sharp & Dohme Corp. Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
EP3316888A1 (en) * 2015-07-02 2018-05-09 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors

Also Published As

Publication number Publication date
CL2020000973A1 (es) 2020-12-28
EP3694520A1 (en) 2020-08-19
JP2024001071A (ja) 2024-01-09
KR20200068655A (ko) 2020-06-15
MX2024001888A (es) 2024-02-29
BR112020007203A2 (pt) 2020-10-20
WO2019075366A1 (en) 2019-04-18
US20200262919A1 (en) 2020-08-20
EA202090565A1 (ru) 2020-10-13
IL273805A (en) 2020-05-31
CN111212646A (zh) 2020-05-29
AU2018347457A1 (en) 2020-04-09
JP2020536923A (ja) 2020-12-17
SG11202002374RA (en) 2020-04-29
TW201922283A (zh) 2019-06-16
CA3075291A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12022550348A1 (en) Materials and methods for improved single chain variable fragments
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2024001888A (es) Composiciones y metodos para tratar linfoma difuso de celulas b grandes.
SA518391159B1 (ar) مترافقات الألفة- قليلة النيوكليوتيد واستخداماتها
MX2021003169A (es) Metodos para purificar anticuerpos multiespecificos, heterodimericos.
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2019007020A (es) Anticuerpos il-11.
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
EA201792443A1 (ru) МОДУЛЯТОРЫ K-Ras
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
GEP20247583B (en) Methods for treating condi tions associated with masp-2 dependent complement activation
SG11201906123VA (en) Method for random access and terminal device
MX2020006297A (es) Variantes de cd19.
EA201991818A1 (ru) Лечение рака
MX382996B (es) Inhibidores de pcna
PH12019500070A1 (en) Uses of indolinone compounds
PH12020551292A1 (en) Moscato wine replicas produced from individual components
MX2018016196A (es) Metodos para muestrear metabolitos gingivales.
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
EP4354134A3 (en) Sorbents, devices, kits and methods useful for biological sample treatment
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
MX2016009541A (es) Metodo para tratar vajilla.